It's currently recommended that patients at average risk for colorectal cancer repeat a colonoscopy every 10 years. Is the 10-year interval appropriate for average-risk patients, or would patients benefit from more frequent colonoscopies? What evidence do we have to support the idea that more frequent colonoscopies would provide more accurate screening? Or, would a shorter intervals between colonoscopies unnecessarily increase cost and inconvenience, without much added benefit? Dr. Mark DeLegge hosts a point-counterpoint discussion. Dr. David Lieberman, professor of medicine at Oregon Health and Science University, supports the standard interval, while Dr. Andrew Chan, assistant professor of medicine at Harvard Medical School, challenges the idea that a screening every 10 years is appropriate for most average-risk patients.
Colonoscopy: Is the 10-Year Interval Too Long?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
It's currently recommended that patients at average risk for colorectal cancer repeat a colonoscopy every 10 years. Is the 10-year interval appropriate for average-risk patients, or would patients benefit from more frequent colonoscopies? What evidence do we have to support the idea that more frequent colonoscopies would provide more accurate screening? Or, would a shorter intervals between colonoscopies unnecessarily increase cost and inconvenience, without much added benefit? Dr. Mark DeLegge hosts a point-counterpoint discussion. Dr. David Lieberman, professor of medicine at Oregon Health and Science University, supports the standard interval, while Dr. Andrew Chan, assistant professor of medicine at Harvard Medical School, challenges the idea that a screening every 10 years is appropriate for most average-risk patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolving Our View of the Coagulation Cascade and Stroke Management
Don’t Wait to Escalate—Getting Aggressive in PH Management
Cardiorenal Collaboration: Optimizing Multidisciplinary Care in the CvRM Patient
Biomarkers of the Storm: Decoding IRI’s Signature
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?